{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:35:46Z","timestamp":1792611346286,"version":"4.5.0"},"reference-count":257,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["31003A-120400"],"award-info":[{"award-number":["31003A-120400"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030-156384"],"award-info":[{"award-number":["310030-156384"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00278","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T03:47:41Z","timestamp":1495424861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":120,"title":["Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases"],"prefix":"10.3389","volume":"8","author":[{"given":"Gabriele","family":"Fenini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Contassot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","article-title":"Proteolytic processing of interleukin-1 family cytokines: variations on a common theme.","volume":"42","author":"Afonina","year":"2015","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1002\/art.10688","article-title":"De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.","volume":"46","author":"Aksentijevich","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1346-8138.13381","article-title":"Behcet\u2019s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions.","volume":"43","author":"Alpsoy","year":"2016","journal-title":"J. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2012.08.003","article-title":"A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset.","volume":"145","author":"Altiok","year":"2012","journal-title":"Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.jaad.2013.12.041","article-title":"Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra.","volume":"71","author":"Amazan","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V84.4.1342.1342","article-title":"Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.","volume":"84","author":"Antin","year":"1994","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2002-03-0985","article-title":"Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.","volume":"100","author":"Antin","year":"2002","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-13-S1-O58","article-title":"Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study.","author":"Ar\u00f3stegui","year":"2015","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/art.22966","article-title":"NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.","volume":"56","author":"Ar\u00f3stegui","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00006","article-title":"IL-1 vaccination is suitable for treating inflammatory diseases.","volume":"8","author":"Assier","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00109-014-1150-5","article-title":"Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases.","volume":"92","author":"Bachetti","year":"2014","journal-title":"J. Mol. Med."},{"key":"B13","article-title":"Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes.","volume":"27","author":"Beeson","year":"1948","journal-title":"J. Clin. Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine resistant familial Mediterranean fever - A randomized, double blind, placebo-controlled trial.","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0009-8981(85)90195-0","article-title":"Mevalonic aciduria: an inborn error of cholesterol biosynthesis?","volume":"152","author":"Berger","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1208\/s12248-014-9623-6","article-title":"Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.","volume":"16","author":"Bihorel","year":"2014","journal-title":"AAPS J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jmb.2012.09.021","article-title":"One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta.","volume":"425","author":"Blech","year":"2013","journal-title":"J. Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency.","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B19","first-page":"260","article-title":"Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.","volume":"63","author":"Bodar","year":"2005","journal-title":"Neth. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.smim.2013.10.023","article-title":"The interleukin-1 receptor family.","volume":"25","author":"Boraschi","year":"2013","journal-title":"Semin. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.4049\/jimmunol.1202121","article-title":"Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner.","volume":"189","author":"Bossaller","year":"2012","journal-title":"J. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrd1342","article-title":"Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention.","volume":"3","author":"Braddock","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2013a new autoinflammatory syndrome distinct from PAPA syndrome.","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.","volume":"161","author":"Brenner","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/art.38777","article-title":"Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.","volume":"66","author":"Brik","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.7326\/0003-4819-156-12-201206190-00027","article-title":"Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab.","volume":"156","author":"Brizi","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/RHU.0b013e318278b84c","article-title":"Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor alpha therapy.","volume":"18","author":"Bruzzese","year":"2012","journal-title":"J. Clin. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1172\/JCI71543","article-title":"Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.","volume":"123","author":"Brydges","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2009.05.005","article-title":"Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.","volume":"30","author":"Brydges","year":"2009","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1172\/JCI118045","article-title":"The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.","volume":"96","author":"Burger","year":"1995","journal-title":"J. Clin. Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bjd.14383","article-title":"PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome.","volume":"175","author":"Calderon-Castrat","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00431-007-0547-3","article-title":"The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.","volume":"167","author":"Calligaris","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome.","volume":"46","author":"Canna","year":"2014","journal-title":"Nat. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series.","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B35","first-page":"560","article-title":"An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity.","volume":"14","author":"Carrasco","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still\u2019s disease: advances in the treatment.","volume":"30","author":"Castaneda","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/mt.2015.227","article-title":"Development of an interleukin-1beta vaccine in patients with type 2 diabetes.","volume":"24","author":"Cavelti-Weder","year":"2016","journal-title":"Mol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1073\/pnas.0602081103","article-title":"The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production.","volume":"103","author":"Chae","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B39","first-page":"187","article-title":"Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases.","volume":"54","author":"Chamot","year":"1987","journal-title":"Rev. Rhum. Mal. Osteoartic."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/jcp.24903","article-title":"Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy.","volume":"230","author":"Chang","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006052","article-title":"Functional and evolutionary analyses identify proteolysis as a general mechanism for NLRP1 inflammasome activation.","volume":"12","author":"Chavarria-Smith","year":"2016","journal-title":"PLoS Pathog."},{"key":"B42","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm1603","article-title":"Identification of a key pathway required for the sterile inflammatory response triggered by dying cells.","volume":"13","author":"Chen","year":"2007","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160937","article-title":"Commensal bacteria-induced inflammasome activation in mouse and human macrophages is dependent on potassium efflux but does not require phagocytosis or bacterial viability.","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","article-title":"Systemic-onset juvenile idiopathic arthritis.","volume":"15","author":"Cimaz","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamadermatol.2014.5391","article-title":"Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1alpha, for the treatment of psoriasis.","volume":"151","author":"Coleman","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","article-title":"Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra.","volume":"49","author":"Colina","year":"2010","journal-title":"Rheumatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/ard.2005.045245","article-title":"Beneficial response to anakinra and thalidomide in Schnitzler\u2019s syndrome.","volume":"65","author":"de Koning","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jaci.2011.05.023","article-title":"Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome.","volume":"128","author":"de Koning","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler\u2019s syndrome.","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome.","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1alpha and the inflammatory process.","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome.","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"Diagnosis and management of acute graft-versus-host disease.","volume":"158","author":"Dignan","year":"2012","journal-title":"Br. J. Haematol."},{"key":"B55","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease.","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family.","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","article-title":"Blocking interleukin-1beta in acute and chronic autoinflammatory diseases.","volume":"269","author":"Dinarello","year":"2011","journal-title":"J. Intern. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1084\/jem.139.6.1369","article-title":"Demonstration and characterization of two distinct human leukocytic pyrogens.","volume":"139","author":"Dinarello","year":"1974","journal-title":"J. Exp. Med."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein.","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1073\/pnas.74.10.4624","article-title":"Human leukocytic pyrogen: purification and development of a radioimmunoassay.","volume":"74","author":"Dinarello","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002001","article-title":"Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions.","volume":"3","author":"Dombrowski","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1093\/rheumatology\/kem231","article-title":"Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).","volume":"46","author":"Drewe","year":"2007","journal-title":"Rheumatology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/bjd.13668","article-title":"First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome.","volume":"173","author":"Duchatelet","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B66","first-page":"354","article-title":"Successful use of anakinra to treat refractory Schnitzler\u2019s syndrome.","volume":"26","author":"Dybowski","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Behcet\u2019s disease: a multicenter retrospective study.","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study.","volume":"36","author":"Fabiani","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"B69","year":"2016","journal-title":"FDA Approves Expanded Indications for Ilaris for Three Rare Diseases."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.cub.2007.05.074","article-title":"The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes.","volume":"17","author":"Feldmeyer","year":"2007","journal-title":"Curr. Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejcb.2010.04.008","article-title":"Interleukin-1, inflammasomes and the skin.","volume":"89","author":"Feldmeyer","year":"2010","journal-title":"Eur. J. Cell Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"18055","DOI":"10.1073\/pnas.1109176108","article-title":"Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression.","volume":"108","author":"Fettelschoss","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0583-y","article-title":"SAPHO syndrome: current developments and approaches to clinical treatment.","volume":"18","author":"Firinu","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-065X.2008.00734.x","article-title":"Function of Nod-like receptors in microbial recognition and host defense.","volume":"227","author":"Franchi","year":"2009","journal-title":"Immunol. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","article-title":"A candidate gene for familial Mediterranean fever.","volume":"17","year":"1997","journal-title":"Nat. Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1128\/CMR.00021-11","article-title":"The Malassezia genus in skin and systemic diseases.","volume":"25","author":"Gaitanis","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B77","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jdcr.2016.07.007","article-title":"The role of interleukin-1beta in pyoderma gangrenosum.","volume":"2","author":"Galimberti","year":"2016","journal-title":"JAAD Case Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","article-title":"Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.","volume":"76","author":"Gattorno","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1084\/jem.136.1.128","article-title":"Potentiation of the T-lymphocyte response to mitogens. I. The responding cell.","volume":"136","author":"Gery","year":"1972","journal-title":"J. Exp. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/2013.jamadermatol.717","article-title":"Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.","volume":"149","author":"Geusau","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis.","volume":"7","author":"Giancane","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"765","DOI":"10.4161\/mabs.28614","article-title":"A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy.","volume":"6","author":"Goh","year":"2014","journal-title":"MAbs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11926-011-0165-y","article-title":"Current status of understanding the pathogenesis and management of patients with NOMID\/CINCA.","volume":"13","author":"Goldbach-Mansky","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0604-7","article-title":"The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-kappaB pathway.","volume":"17","author":"Greco","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ni.2222","article-title":"Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome.","volume":"13","author":"Gringhuis","year":"2012","journal-title":"Nat. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.immuni.2016.08.010","article-title":"K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria.","volume":"45","author":"Gross","year":"2016","journal-title":"Immunity"},{"key":"B90","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2012.01.018","article-title":"Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1.","volume":"36","author":"Gross","year":"2012","journal-title":"Immunity"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0765-4","article-title":"Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.","volume":"17","author":"G\u00fcl","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-1-13","article-title":"Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome.","volume":"1","author":"Haas","year":"2006","journal-title":"Orphanet J. Rare Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-beta.","volume":"9","author":"Halle","year":"2008","journal-title":"Nat. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/ni.2749","article-title":"Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity.","volume":"14","author":"Hara","year":"2013","journal-title":"Nat. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.","volume":"348","author":"Hawkins","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion.","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.chom.2009.05.002","article-title":"An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans.","volume":"5","author":"Hise","year":"2009","journal-title":"Cell Host Microbe"},{"key":"B101","article-title":"\u201cSafety and efficacy of long-term canakinumab therapy in patients with CAPS: final results from beta-confident registry,\u201d in","author":"Hoffman","year":"2016","journal-title":"Proceedings of the 2016 ACR\/ARHP Annual Meeting"},{"key":"B102","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat. Genet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.","volume":"364","author":"Hoffman","year":"2004","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B105","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1073\/pnas.0802726105","article-title":"A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.","volume":"105","author":"Hsu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B108","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/jcp.24815","article-title":"Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1beta production.","volume":"230","author":"Hua","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"B109","author":"Huang","year":"2014","journal-title":"Results of An Open-Label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum."},{"key":"B110","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00005792-200209000-00002","article-title":"The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.","volume":"81","author":"Hull","year":"2002","journal-title":"Medicine"},{"key":"B111","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000371879","article-title":"Severe sweet\u2019s syndrome with elevated cutaneous interleukin-1beta after azathioprine exposure: case report and review of the literature.","volume":"230","author":"Imhof","year":"2015","journal-title":"Dermatology"},{"key":"B112","year":"2017","journal-title":"Infevers: An Online Database for Autoinflammatory Mutations."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8360","article-title":"Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.","volume":"6","author":"Ito","year":"2015","journal-title":"Nat. Commun."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1186\/ar4483","article-title":"CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction.","volume":"16","author":"Ito","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-35","article-title":"Acute graft versus host disease.","volume":"2","author":"Jacobsohn","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa\u2013rapid response to canakinumab (anti-IL-1beta).","volume":"23","author":"Jaeger","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1084\/jem.20130084","article-title":"The Nlrp3 inflammasome regulates acute graft-versus-host disease.","volume":"210","author":"Jankovic","year":"2013","journal-title":"J. Exp. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/art.38727","article-title":"Brief report: involvement of TNFRSF11A molecular defects in autoinflammatory disorders.","volume":"66","author":"Jeru","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1073\/pnas.0708616105","article-title":"Mutations in NALP12 cause hereditary periodic fever syndromes.","volume":"105","author":"Jeru","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1002\/art.21050","article-title":"Interaction of pyrin with 14.3.3 in an isoform-specific and phosphorylation-dependent manner regulates its translocation to the nucleus.","volume":"52","author":"Jeru","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B121","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes.","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa061592","article-title":"NALP1 in vitiligo-associated multiple autoimmune disease.","volume":"356","author":"Jin","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1073\/pnas.1400075111","article-title":"Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome.","volume":"111","author":"Kailasan Vanaja","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1111\/jdv.13856","article-title":"High level of serum human interleukin-18 in a patient with pyogenic arthritis, pyoderma gangrenosum and acne syndrome.","volume":"31","author":"Kanameishi","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11.","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"B127","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2007.12.040","article-title":"Active caspase-1 is a regulator of unconventional protein secretion.","volume":"132","author":"Keller","year":"2008","journal-title":"Cell"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00391","article-title":"The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines.","volume":"4","author":"Kim","year":"2013","journal-title":"Front. Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/exd.12552","article-title":"Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling.","volume":"23","author":"Kistowska","year":"","journal-title":"Exp. Dermatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2013.438","article-title":"IL-1beta drives inflammatory responses to propionibacterium acnes in vitro and in vivo.","volume":"134","author":"Kistowska","year":"","journal-title":"J. Invest. Dermatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1084\/jem.20141091","article-title":"An inherited mutation in NLRC4 causes autoinflammation in human and mice.","volume":"211","author":"Kitamura","year":"2014","journal-title":"J. Exp. Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet\u2019s syndrome.","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum.","volume":"173","author":"Kolios","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00369","article-title":"Curcumin represses NLRP3 inflammasome activation via TLR4\/MyD88\/NF-kappaB and P2X7R signaling in PMA-induced macrophages.","volume":"7","author":"Kong","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","article-title":"The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still\u2019s disease.","volume":"42","author":"Kontzias","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jaci.2016.07.041","article-title":"Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study.","volume":"139","author":"Krause","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1398-9995.2012.02843.x","article-title":"Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.","volume":"70","author":"Kuemmerle-Deschner","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).","volume":"13","author":"Kuemmerle-Deschner","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B140","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","article-title":"What causes hidradenitis suppurativa?","volume":"17","author":"Kurzen","year":"2008","journal-title":"Exp. Dermatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome.","volume":"360","author":"Lachmann","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome.","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J. Cell Biol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3899\/jrheum.160518","article-title":"Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever.","volume":"44","author":"Laskari","year":"2017","journal-title":"J. Rheumatol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature11588","article-title":"The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP.","volume":"492","author":"Lee","year":"2012","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.1073\/pnas.0402800101","article-title":"Differences in signaling pathways by IL-1beta and IL-18.","volume":"101","author":"Lee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B146","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1189\/jlb.2MR0316-117RR","article-title":"Molecular mechanisms of regulation of Toll-like receptor signaling.","volume":"100","author":"Leifer","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.","volume":"70","author":"Leslie","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000443648","article-title":"PASS syndrome: an IL-1-driven autoinflammatory disease.","volume":"232","author":"Leuenberger","year":"2016","journal-title":"Dermatology"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3892\/or.2015.4176","article-title":"Protective effect of neutralizing anti-IL-18alpha monoclonal antibody on a mouse model of acute graft-versus-host disease.","volume":"34","author":"Li","year":"2015","journal-title":"Oncol. Rep."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1038\/jid.2014.221","article-title":"Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes.","volume":"134","author":"Li","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.","volume":"174","author":"Lima","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0025-6196(11)63565-9","article-title":"A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin. Proc."},{"key":"B153","doi-asserted-by":"crossref","DOI":"10.1002\/9781118441213.rtd0046","article-title":"\u201cAutoinflammatory diseases presenting in the skin,\u201d in","author":"Lipsker","year":"2016","journal-title":"Rook\u2019s Textbook of Dermatology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jbspin.2013.12.011","article-title":"Canakinumab in a case of adult onset still\u2019s disease: efficacy only on systemic manifestations.","volume":"81","author":"Lo Gullo","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.20953","article-title":"Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.","volume":"52","author":"Lovell","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00285","article-title":"Unsolved mysteries in NLR biology.","volume":"4","author":"Lupfer","year":"2013","journal-title":"Front. Immunol."},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11813","article-title":"Crystal structure of NOD2 and its implications in human disease.","volume":"7","author":"Maekawa","year":"2016","journal-title":"Nat. Commun."},{"key":"B159","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri.2015.7","article-title":"Converging roles of caspases in inflammasome activation, cell death and innate immunity.","volume":"16","author":"Man","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1002\/art.22194","article-title":"A role for geranylgeranylation in interleukin-1beta secretion.","volume":"54","author":"Mandey","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jamadermatol.2015.1684","article-title":"Reporting of MABp1 for the treatment of psoriasis.","volume":"151","author":"Mansouri","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab.","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature02664","article-title":"Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf.","volume":"430","author":"Mariathasan","year":"2004","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature04515","article-title":"Cryopyrin activates the inflammasome in response to toxins and ATP.","volume":"440","author":"Mariathasan","year":"2006","journal-title":"Nature"},{"key":"B165","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell."},{"key":"B166","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B167","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000246219","article-title":"Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity?","volume":"193","author":"Marzano","year":"1996","journal-title":"Dermatology"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000187","article-title":"Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases.","volume":"93","author":"Marzano","year":"","journal-title":"Medicine"},{"key":"B169","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet\u2019s syndrome.","volume":"178","author":"Marzano","year":"","journal-title":"Clin. Exp. Immunol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","article-title":"Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene.","volume":"149","author":"Marzano","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clim.2012.12.006","article-title":"Specific inflammasomes in complex diseases.","volume":"147","author":"Masters","year":"2013","journal-title":"Clin. Immunol."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1471","article-title":"Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.","volume":"8","author":"Masters","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0328-z","article-title":"Behcet syndrome: from pathogenesis to novel therapies.","volume":"16","author":"Mazzoccoli","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150018","article-title":"A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus.","volume":"11","author":"McKie","year":"2016","journal-title":"PLoS ONE"},{"key":"B176","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4049\/jimmunol.0901346","article-title":"Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3.","volume":"184","author":"Meixenberger","year":"2010","journal-title":"J. Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bjd.13292","article-title":"Two cases of severe hidradenitis suppurativa with failure of anakinra therapy.","volume":"172","author":"Menis","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1073\/pnas.0913087107","article-title":"Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome.","volume":"107","author":"Miao","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B179","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng720","article-title":"CARD15 mutations in Blau syndrome.","volume":"29","author":"Miceli-Richard","year":"2001","journal-title":"Nat. Genet."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.4049\/jimmunol.0900729","article-title":"A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.","volume":"183","author":"Munoz-Planillo","year":"2009","journal-title":"J. Immunol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter.","volume":"38","author":"Munoz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"B182","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.1117765109","article-title":"Critical role for calcium mobilization in activation of the NLRP3 inflammasome.","volume":"109","author":"Murakami","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B183","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response.","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"key":"B184","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/IAI.61.1.64-70.1993","article-title":"Purification of a factor which provides a costimulatory signal for gamma interferon production.","volume":"61","author":"Nakamura","year":"1993","journal-title":"Infect. Immun."},{"key":"B185","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/IAI.57.2.590-595.1989","article-title":"Endotoxin-induced serum factor that stimulates gamma interferon production.","volume":"57","author":"Nakamura","year":"1989","journal-title":"Infect. Immun."},{"key":"B186","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-015-0549-6","article-title":"Neutrophilic dermatoses and autoinflammatory diseases with skin involvement\u2013innate immune disorders.","volume":"38","author":"Navarini","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"B187","article-title":"\u201cSafety and efficacy of rilonacept in patients with deficiency of interleukin-1 receptor antagonist (DIRA),\u201d in","author":"Neal","year":"2014","journal-title":"Proceedings of the 2014 ACR\/ARHP Annual Meeting"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.4049\/jimmunol.175.3.1776","article-title":"The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes.","volume":"175","author":"Niyonsaba","year":"2005","journal-title":"J. Immunol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study.","volume":"39","author":"Nordstrom","year":"2012","journal-title":"J. Rheumatol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"32926","DOI":"10.1074\/jbc.M114.579961","article-title":"The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation.","volume":"289","author":"Okada","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B191","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.","volume":"17","author":"Park","year":"2016","journal-title":"Nat. Immunol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis.","volume":"7","author":"Perera","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration.","volume":"14","author":"Petrilli","year":"2007","journal-title":"Cell Death Differ."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 Trap rilonacept in refractory adult onset Still\u2019s disease.","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B195","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/jid.2012.162","article-title":"Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa).","volume":"132","author":"Pink","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation.","volume":"197","author":"Primiano","year":"2016","journal-title":"J. Immunol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/jid.2013.309","article-title":"Propionibacterium acnes induces IL-1beta secretion via the NLRP3 inflammasome in human monocytes.","volume":"134","author":"Qin","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature11429","article-title":"Phosphorylation of NLRC4 is critical for inflammasome activation.","volume":"490","author":"Qu","year":"2012","journal-title":"Nature"},{"key":"B199","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1084\/jem.20132234","article-title":"NLRP3 recruitment by NLRC4 during Salmonella infection.","volume":"213","author":"Qu","year":"2016","journal-title":"J. Exp. Med."},{"key":"B200","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus.","volume":"360","author":"Reddy","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00342","article-title":"Pattern recognition and signaling mechanisms of RIG-I and MDA5.","volume":"5","author":"Reikine","year":"2014","journal-title":"Front. Immunol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","article-title":"Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation.","volume":"46","author":"Romberg","year":"2014","journal-title":"Nat. Genet."},{"key":"B204","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1084\/jem.150.3.709","article-title":"Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen.","volume":"150","author":"Rosenwasser","year":"1979","journal-title":"J. Exp. Med."},{"key":"B205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2310\/7750.2008.07050","article-title":"Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up.","volume":"12","author":"Ross","year":"2008","journal-title":"J. Cutan. Med. Surg."},{"key":"B206","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B207","first-page":"772","article-title":"Failure of anakinra in a case of severe hidradenitis suppurativa.","volume":"15","author":"Russo","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/j.jaad.2014.10.002","article-title":"PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.","volume":"72","author":"Saraceno","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1525-1470.2012.01725.x","article-title":"Deficiency of interleukin-1 receptor antagonist responsive to anakinra.","volume":"30","author":"Schnellbacher","year":"2013","journal-title":"Pediatr. Dermatol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes.","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"B211","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ni.3333","article-title":"NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component.","volume":"17","author":"Shi","year":"2016","journal-title":"Nat. Immunol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"B213","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS.","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"key":"B214","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis.","volume":"36","author":"Shimada","year":"2012","journal-title":"Immunity"},{"key":"B215","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.1073\/pnas.2135380100","article-title":"Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway.","volume":"100","author":"Shoham","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B217","doi-asserted-by":"crossref","first-page":"R1264","DOI":"10.1152\/ajpregu.2001.281.4.R1264","article-title":"Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.","volume":"281","author":"Siegmund","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","article-title":"Beneficial response to interleukin 1 receptor antagonist in traps.","volume":"117","author":"Simon","year":"2004","journal-title":"Am. J. Med."},{"key":"B219","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B220","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/gut.50.6.812","article-title":"Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage.","volume":"50","author":"Sivakumar","year":"2002","journal-title":"Gut"},{"key":"B221","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2337\/dc12-1835","article-title":"Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes.","volume":"36","author":"Sloan-Lancaster","year":"2013","journal-title":"Diabetes Care"},{"key":"B222","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3109\/09546634.2015.1136048","article-title":"Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.","volume":"27","author":"Sonnichsen","year":"2016","journal-title":"J. Dermatolog. Treat."},{"key":"B223","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.4049\/jimmunol.175.4.2630","article-title":"IL-converting enzyme\/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients.","volume":"175","author":"Stack","year":"2005","journal-title":"J. Immunol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1073\/pnas.92.5.1714","article-title":"Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.","volume":"92","author":"Symons","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1186\/ar3295","article-title":"Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis.","volume":"13","author":"Takei","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/art.39763","article-title":"The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the eurofever registry.","volume":"68","author":"Ter Haar","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jdiacomp.2015.05.019","article-title":"Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus.","volume":"29","author":"Timper","year":"2015","journal-title":"J. Diabetes Complications"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/795027","article-title":"A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab.","volume":"2013","author":"Tsitsami","year":"2013","journal-title":"Case Rep. Rheumatol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial.","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-015-0618-4","article-title":"Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report.","volume":"9","author":"Ulusoy","year":"2015","journal-title":"J. Med. Case Rep."},{"key":"B231","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.4049\/jimmunol.156.11.4274","article-title":"Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein.","volume":"156","author":"Ushio","year":"1996","journal-title":"J. Immunol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.clim.2012.09.011","article-title":"Mevalonate kinase deficiency, a metabolic autoinflammatory disease.","volume":"147","author":"van der Burgh","year":"2013","journal-title":"Clin. Immunol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(84)92505-4","article-title":"Hyperimmunoglobulinaemia D and periodic fever: a new syndrome.","volume":"1","author":"van der Meer","year":"1984","journal-title":"Lancet"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta.","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"B236","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.semarthrit.2012.06.003","article-title":"Canakinumab in Schnitzler syndrome.","volume":"42","author":"Vanderschueren","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"B237","year":"2007","journal-title":"Vertex Form 10-K Annual Report."},{"key":"B238","year":"2011","journal-title":"Vertex Form 10-K Annual Report."},{"key":"B239","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations.","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"B240","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet\u2019s disease: a case series.","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"B241","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","article-title":"(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18.","volume":"321","author":"Wannamaker","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.3105cm1","article-title":"Interleukin-1 (IL-1) pathway.","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","article-title":"Anakinra treatment of SAPHO syndrome: short-term results of an open study.","volume":"71","author":"Wendling","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B244","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1073\/pnas.0308705101","article-title":"The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription.","volume":"101","author":"Werman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B245","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/370270a0","article-title":"Structure and mechanism of interleukin-1 beta converting enzyme.","volume":"370","author":"Wilson","year":"1994","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","article-title":"Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder.","volume":"11","author":"Wise","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"B247","year":"2017","journal-title":"XBiotech Meets Primary Endpoint in Phase 2 Study ofMABp1 for Treatment of Hidradenitis Suppurativa (HS)."},{"key":"B248","year":"2013","journal-title":"XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris."},{"key":"B249","year":"2015","journal-title":"XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study."},{"key":"B250","year":"2016","journal-title":"XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results."},{"key":"B251","article-title":"Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.","author":"Yokota","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra.","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1111\/j.1742-4658.2005.05031.x","article-title":"The C-type lectin-like domain superfamily.","volume":"272","author":"Zelensky","year":"2005","journal-title":"FEBS J."},{"key":"B255","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cell.2016.09.001","article-title":"Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation.","volume":"167","author":"Zhong","year":"2016","journal-title":"Cell"},{"key":"B256","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation.","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"B257","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/mc.20437","article-title":"Resveratrol directly targets COX-2 to inhibit carcinogenesis.","volume":"47","author":"Zykova","year":"2008","journal-title":"Mol. Carcinog."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00278\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:28:58Z","timestamp":1719214138000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00278\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":257,"alternative-id":["10.3389\/fphar.2017.00278"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00278","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]},"article-number":"278"}}